Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay DOI Creative Commons
Njoud Altuwaijri, Rawan Fitaihi, Fai A. Alkathiri

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 417 - 417

Published: March 15, 2025

Background/Objectives: Atorvastatin (ATR), an antihyperlipidemic drug with a potential antibacterial effect, was investigated in this study. Like other statins, ATR has been repurposed for several uses, ranging from anti-inflammatory to antimicrobial applications, and demonstrated successful results. However, the efficacy of is limited by its low solubility, indicating opportunity encapsulation nanotechnology-based delivery system. Methods: Nanostructured lipid carrier (NLC) formulations were prepared using high-pressure homogenization ultrasonication. The characterized, including their particle size, polydispersity index, zeta potential, efficiency, vitro release. Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli), (S. aureus) evaluated growth curve (bacterial over time) well diffusion methods (zone inhibition minimum inhibitory concentration (MIC) determination). crystal violet assay employed assess biofilm inhibition. Results: NLC optimized, size blank nanoparticles 130 ± 8.39 nm −35 0.5 mV, respectively. In comparison, encapsulated NLCs had 142 52.20 −31 1.41 mV. average efficiency 94%, 70% released after 24 h. ATR-loaded showed significantly enhanced reducing 2.5-fold E. coli, 1.8-fold S. aureus, 1.4-fold MRSA, promoting more effective bacterial Notably, improved ATR-NLCs, achieving 80% 40% 30% compared free (p < 0.001). These findings suggest that enhances ATR’s suppression. Conclusions: This study identified as carriers ATR, enhancing capabilities. formulation, which shows both Gram-positive Gram-negative bacteria, should be further studied developed different resistant microbial strains.

Language: Английский

Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay DOI Creative Commons
Njoud Altuwaijri, Rawan Fitaihi, Fai A. Alkathiri

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 417 - 417

Published: March 15, 2025

Background/Objectives: Atorvastatin (ATR), an antihyperlipidemic drug with a potential antibacterial effect, was investigated in this study. Like other statins, ATR has been repurposed for several uses, ranging from anti-inflammatory to antimicrobial applications, and demonstrated successful results. However, the efficacy of is limited by its low solubility, indicating opportunity encapsulation nanotechnology-based delivery system. Methods: Nanostructured lipid carrier (NLC) formulations were prepared using high-pressure homogenization ultrasonication. The characterized, including their particle size, polydispersity index, zeta potential, efficiency, vitro release. Antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli), (S. aureus) evaluated growth curve (bacterial over time) well diffusion methods (zone inhibition minimum inhibitory concentration (MIC) determination). crystal violet assay employed assess biofilm inhibition. Results: NLC optimized, size blank nanoparticles 130 ± 8.39 nm −35 0.5 mV, respectively. In comparison, encapsulated NLCs had 142 52.20 −31 1.41 mV. average efficiency 94%, 70% released after 24 h. ATR-loaded showed significantly enhanced reducing 2.5-fold E. coli, 1.8-fold S. aureus, 1.4-fold MRSA, promoting more effective bacterial Notably, improved ATR-NLCs, achieving 80% 40% 30% compared free (p < 0.001). These findings suggest that enhances ATR’s suppression. Conclusions: This study identified as carriers ATR, enhancing capabilities. formulation, which shows both Gram-positive Gram-negative bacteria, should be further studied developed different resistant microbial strains.

Language: Английский

Citations

0